Abstract: The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R1, R2A, R2B, R2C, R2D, W, X, Y, and Z have the meanings defined herein. Such compounds are useful in inhibiting NLRP3 inflammasome activity and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions in which the NLRP3 inflammasome is implicated. The specification further relates to compositions comprising such compounds.

Abstract: The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R1, R2A, R2B, R2C, R2D, W, X, Y, and Z have the meanings defined herein. Such compounds are useful in inhibiting NLRP3 inflammasome activity and may be useful as therapeutic agents. The specification also relates to the use of such compounds to treat or prevent diseases and conditions in which the NLRP3 inflammasome is implicated. The specification further relates to compositions comprising such compounds.

Abstract: An iontophoresis device including an active electrode assembly or a counter electrode assembly with a polarizable electrode containing any one of a conductive material having a capacitance per unit weight of 1 F/g or greater, a conductive material having a specific surface area of 10 m2/g or greater, and activated carbon is disclosed. The generation of gas or ions due to an electrode reaction occurring in an electrode assembly may be reduced or prevented. In addition, the alteration of an active agent due to a chemical reaction upon energization may be reduced or prevented.

Abstract: An iontophoresis device may be capable of preventing or reducing the generation of gas, or the production of undesirable ions, due to an electrode reaction occurring in an electrode assembly; or the alteration of an active agent due to a chemical reaction upon energization. A doping layer made of a substance such as a conductive polymer that effects an electrochemical reaction due to the doping or de-doping of an ion, may be formed in an electrode in an active electrode assembly or counter electrode assembly of an iontophoresis device.

Abstract: The objective is to obtain fuel having high combustion calorie and superior handleability from a crude glycerin or a fatty acid mixture that have been discarded as industrial waste products. Disclosed is a fuel comprising a water-insolublized fatty acid substance obtained by water-insolubilizing a fatty acid that is contained in a crude glycerin or fatty acid mixtures that are produced as by-products in the process of producing a biofuel from an animal/plant-derived fat/oil. The water-insolublized fatty acid substance is preferably a water-insoluble fatty acid salt, particularly preferably a salt of a fatty acid with a divalent or trivalent metal ion.

Abstract: Provided is a liquid mixing device capable of mixing together two or more kinds of liquids successively in an accurate ratio. The liquid mixing device includes: a first supply system for supplying a first liquid; a second supply system for supplying a second liquid; and a liquid mixing system that receives supply of the first liquid and second liquid from the first supply system and the second supply system, respectively, in which: the first supply system communicates to the liquid mixing system through a first flow rate regulation unit having a first path sectional area; the second supply system is connected to the liquid mixing system through a second flow rate regulation unit having a second path sectional area; and the first liquid in an amount corresponding to the first path sectional area and the second liquid in an amount corresponding to the second path sectional area are allowed to flow into the liquid mixing system, respectively, by making an inside pressure of the liquid mixing system negative.

Abstract: The present invention provides aromatic nitrogen-containing 6-membered ring compounds having excellent PDE10 inhibitory activity.

Abstract: The present invention provides a tri-substituted pyrimidine compound having an excellent PDE10 inhibitory activity. The present invention relates to a tri-substituted pyrimidine compound represented by the following formula [I0] or a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of said compound for PDE10 inhibitor, and a pharmaceutical composition comprising said compounds as an active ingredient: wherein: either one of X1 and X2 is N, and the other of X1 and X2 is CH; A is *-CH?CH—, *-C(Alk)=CH—, *-CH2—CH2— or *-O—CH2— (* is a bond with R1); Alk is a lower alkyl group; Ring B is an optionally substituted nitrogen-containing aliphatic heterocyclic group; R1 is an optionally substituted quinoxalinyl or an optionally substituted quinolyl; Y0 is mono- or di-substituted amino group, or a pharmaceutically acceptable salt thereof.

Abstract: An shaped iontophoresis device is capable of permeating an active agent (e.g., a drug solution) into an oral cavity, a skin cancer, or the like by iontophoresis in a pinpoint manner. A catheter-type iontophoresis device includes a small working electrode assembly and a small non-working electrode assembly at the tip of a holding portion. A first ion exchange membrane and a fourth ion exchange membrane at the tips of the assemblies are brought into close contact with a target area so that a drug solution is permeated by iontophoresis in a pinpoint manner. The working electrode assembly and the non-working electrode assembly are attached to the tip of a rod-shaped member. The rod-shaped member is detachable from the tip of the holding portion, and is exchangeable integrally with the portion. The iontophoresis device may advantageously take the form of a rod or catheter.

Abstract: The present invention provides an iontophoresis device with high administration efficient of a drug. An iontophoresis device, including an active electrode structure including: an electrode to which a positive electrical potential is applied; a drug holding part for holding a drug solution containing positively charged drug ions, the drug holding part being placed on a front side of the electrode; a cellulose-based resin film placed on a front side of the drug holding part or a complex film composed of a cation exchange membrane and a cellulose-based resin film placed on a front side of the cation exchange membrane, the complex film being placed on a front side of the drug holding part, in which the drug ions are administered through the cellulose-based resin film.

Abstract: The present invention provides an iontophoresis device with high administration efficient of a drug. An iontophoresis device, including an active electrode structure including: an electrode to which a positive electrical potential is applied; a drug holding part for holding a drug solution containing positively charged drug ions, the drug holding part being placed on a front side of the electrode; a cellulose-based resin film placed on a front side of the drug holding part or a complex film composed of a cation exchange membrane and a cellulose-based resin film placed on a front side of the cation exchange membrane, the complex film being placed on a front side of the drug holding part, in which the drug ions are administered through the cellulose-based resin film.

Abstract: The transport efficiency of a drug using an iontophoresis device is increased using a negative pressure device. The iontophoresis device includes a working electrode assembly and a non-working electrode assembly for administering drug by iontophoresis. Each of the working electrode assembly and the non-working electrode assembly includes an adhesive surface configured to adhere to a biological interface. A DC electric power source is connected to the working electrode assembly and the non-working electrode assembly. The iontophoresis device further includes a negative pressure device integral with at least one of the working electrode assembly and the non-working electrode assembly and configured to maintain a negative pressure between the at least one of the working electrode assembly and the non-working electrode assembly and the biological interface.

Abstract: An iontophoresis device including an electric power source. A first electrode assembly is electrically coupled to the electric power source to transdermally administer an ionic drug to an organism via iontophoresis while a second electrode assembly is electrically coupled to the electric power source as a counter electrode to the first electrode assembly. A sensor may be positioned proximate an internal or external portion of the organism and operable to determine information used to select and deliver the ionic drug to the organism.

Abstract: An iontophoresis device may include an electrolyte solution holding portion and a drug solution holding portion. The electrolyte solution holding portion holds a solution of an electrolyte that dissociates into a first electrolytic ion of a first polarity type and a second electrolytic ion of a second polarity type in a solution. The drug solution holding portion holds a solution of a drug that dissociates into a drug ion of the first polarity type and a drug counter ion of the second polarity type. The iontophoresis device may also include a first ion exchange membrane with an ion exchange group of the first polarity type and a second ion exchange membrane with an ion exchange group of the second polarity type. The first and the second ion exchange members interpose the electrolyte solution holding portion and the drug solution holding portion.

Abstract: An electrode assembly for iontophoresis including an electrode coupled to an electric power source device having a same polarity as that of the ionic drug in the electrode assembly, an electrolyte solution holding portion holding an electrolyte solution by being impregnated with the electrolyte solution, the electrolyte solution holding portion being placed adjacent to the electrode, a first ion exchange membrane operable to substantially pass ions having a polarity that is same as a polarity of the ionic drug and substantially block ions having a polarity that is opposite the polarity of the ionic drug, the first ion exchange membrane being placed adjacent to the electrolyte solution holding portion, a drug solution holding portion holding the ionic drug by being impregnated with the ionic drug, the drug solution holding portion being placed adjacent to the first ion exchange membrane, a second ion exchange membrane operable to substantially pass ions having a polarity that is opposite the polarity of the io

Abstract: An iontophoresis device capable of stably holding a drug for a long time period and of transdermally administering the drug at a high transport number during use. The iontophoresis device includes a drug holding portion to store the ionic drug in a dry state and at least an aqueous medium holding portion to store an aqueous medium. The drug holding portion exhibiting ion conductivity in response to a needle inserted into the aqueous medium holding portion from outside the electrode assembly such that the drug holding portion is supplied with the aqueous medium during use and the ionic drug dissolves in the aqueous medium.

Abstract: An iontophoresis device capable of stably holding a drug during a storage period and of transdermally administering the drug to an organism at a high transport number during use. The iontophoresis device includes an electric power source. A first electrode assembly may be electrically coupled to the electric power source to store and transdermally administer an ionic drug to an organism via iontophoresis. The first electrode assembly stores the ionic drug at a temperature less than or equal to zero degrees Celsius and administers the ionic drug at a temperature greater than zero degrees Celsius. A second electrode assembly may be electrically coupled to the electric power source as a counter electrode to the first electrode assembly.

Abstract: An iontophoresis device for administering drug ions via the first ion-exchange membrane, comprising a first semi-permeable film having a number of pores passing through the film from a front surface to a back surface, a first ion-exchange membrane formed of ion-exchange resin filling the pores of the first semi-permeable film and selective ions of a first polarity, and a working electrode structure having a drug holding part placed on a back surface of the first ion-exchange membrane and holding a drug solution containing drug ions charged in the first polarity, wherein a layer of a water-soluble polymer compound is chemically bonded on the surface of the first semi-permeable film.

Abstract: A drug may be administered in accordance with a daily living pattern of a patient and/or a circadian rhythm of the drug. An iontophoresis device includes a working electrode assembly and a non-working electrode assembly for administering a drug by iontophoresis and an electric power source connected to the working electrode assembly and the non-working electrode assembly. Current control circuitry programmably controls a current that flows to each of the electrode assemblies according to a set pattern, and the drug is released based at least in part on the current.

Abstract: A catheter-type iontophoresis device is adapted to cause a drug solution to permeate into a cancer site or the like of a digestive organ on a pinpoint basis by iontophoresis. The catheter-type iontophoresis device includes a working electrode assembly and a non-working electrode assembly for administering a drug by iontophoresis. A DC electric power source is connected to the working electrode assembly and the non-working electrode assembly with opposite polarities, and a rod-like member supports the working electrode assembly and the non-working electrode assembly at its tip. The rod-like member is detachably supported at a tip of a flexible cable supported by an endoscopic device.